EMA Seeks to Identify R&D Gaps in Pediatrics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Seeks to Identify R&D Gaps in Pediatrics


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency (EMA) has launched a public consultation concerning its inventory of pediatric medicines with the aim of highlighting where further R&D efforts are required. The consultation is the first of its kind in this area.

The inventory is being developed by EMA’s Pediatric Committee (PDCO) and is based on a survey of all the pediatric uses of medicinal products in Europe, which was completed by PDCO in December 2010. By identifying the needs in different therapeutic areas, PDCO hopes that the inventory will help pharmaceutical companies to identify opportunities for new business development. In addition, the lists will enable PDCO to assess the need for medicines and studies when reviewing draft pediatric investigation plans, waivers, and deferrals. In Europe, all applications for marketing authorizations submitted to EMA must include either a product-specific waiver or pediatric investigation plan.

Healthcare professionals and patients will also be able to make use of the inventory to support their decisions in the choice of medication.

The first list to be released includes all cardiovascular medicines for use in children and is open for consultation until Oct. 30, 2012. Details on how to participate are available on the EMA website. Lists for other therapeutic areas will be released for public consultation during 2012 and 2013.

Related articles

Regulatory Intervention in Pediatric Medicines

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here